Vitality Biopharma (OTCQB: VBIO) is focused on leveraging the power of cannabinoids to treat serious neurological and inflammatory disorders. The company has developed a new class of cannabinoid prodrugs (cannabosides), which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation. For more information, visit the company’s website at www.vitality.bio.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, PNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.
For more information, visit https://www.psychedelicnewswire.com
Please see full disclaimers on the PsychedelicNewsWire website: http://nnw.fm/Disclaimer
PsychedelicNewsWire (PNW)
San Francisco, CO
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…
The new FDA voucher program aims to speed approval of drugs aligned with national health…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…
Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…
Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…